Updated results from pivotal HER2CLIMB trial evaluating Tukysa in patients with HER2-positive breast cancer – Seagen Inc
Seagen Inc. announced the presentation of new data from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in overall survival (OS) was maintained after an additional… read more.
